Clinical-stage biotechnology company.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Cardiff Oncology Inc. in the last 30 days yet.
The 1 sources with the most insights about Cardiff Oncology Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker was short, anticipating a clinical trial failure. After the data release, it was described as 'incrementally bad' and not good enough for the stock to go up, as the drug's advantage over the control arm narrowed significantly.
Speaker is explicitly bearish ahead of a binary data release, stating 'I don't think Cardiff's going to make it' and implying a short position with a 90% chance of failure.
The speaker was short, anticipating a clinical trial failure. After the data release, it was described as 'incrementally bad' and not good enough for the stock to go up, as the drug's advantage over the control arm narrowed significantly.
Speaker is explicitly bearish ahead of a binary data release, stating 'I don't think Cardiff's going to make it' and implying a short position with a 90% chance of failure.
Other assets that creators frequently mention in the same content as Cardiff Oncology Inc..
The most active sources covering Cardiff Oncology Inc. (CRDF) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Cardiff Oncology Inc. (CRDF) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Cardiff Oncology Inc. (CRDF) most frequently also discuss SRPT, ABVX, RGTI, IONQ, QBTS. See the "Discussed alongside" section above for full asset pages.